Dupilumab in patients with cold urticaria: Results from a phase 3 trial
Abstract
Background: Cold urticaria (ColdU) is a chronic inducible urticaria characterized by the appearance of itchy wheals and/or angioedema following contact with cold. Although dupilumab treatment showed significant improvements in chronic spontaneous urticaria, there are currently no approved therapies for ColdU.
Objective: Our aim was to evaluate the efficacy and safety of dupilumab in adult and adolescent patients with ColdU who remain symptomatic despite the use of antihistamines.
Methods: LIBERTY-CINDU CUrIADS (ClinicalTrial.gov identifier NCT04681729) was a phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter trial in which patients aged 12 years or older who had ColdU received dupilumab, 300 mg, or placebo every 2 weeks. The efficacy and safety of dupilumab were assessed after a 24-week treatment period. The primary end point was the proportion of patients with a negative ice cube provocation test result at week 24. The key secondary end points were change from baseline in Peak Pruritus Numeric Rating Scale score at the provocation site, and health-related quality of life, as measured by Dermatology Life Quality Index.
Results: In total, 82 adult patients were enrolled in the study. There were no statistically significant differences between the dupilumab and placebo recipients in terms of primary or secondary end points. The proportion of adult patients with ColdU with treatment-emergent adverse events was lower with dupilumab than with…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 82 participants or records.
Read the paper
Related studies
- Artificial Intelligence in Medicine: Cross-Sectional Study Among Medical Students on Application, Education, and Ethical Aspects
- Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study
- The quality and reliability of short videos about hypertension on TikTok: a cross-sectional study
- Quality and reliability evaluation of pancreatic cancer-related video content on social short video platforms: a cross-sectional study
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study
- Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007–2018
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.